-- Partnership Announced Between Leaders of Artificial Pancreas Research and Development to Develop Novel Redundant Sensor System to Help Improve Glucose Control for People with Diabetes --

THE WOODLANDS, Texas, May 3, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that

A transcription factor activated by too much sugar in the blood is a driver of an implacable cycle of too little insulin resulting in too much sugar in the blood that, in turn, causes failure of beta cells to make enough insulin which results in even higher blood sugar and type 2 diabetes.

--Novel Transmitter Will Simplify Artificial Pancreas Research by Eliminating a Separate CGM component-- NEW YORK, April 24, 2012 /PRNewswire-USNewswire/ -- JDRF, the leading

In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose---- the simple sugar that is the source of energy in human cells and the central player in diabetes.